AstraZeneca stock: FDA clears new Imfinzi bladder regimen
Published on 11/18/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSApproval broadens bladder cancer reach
- The FDA cleared perioperative Imfinzi with enfortumab vedotin for adults with muscle-invasive bladder cancer who cannot receive or have refused cisplatin.
- The VOLGA trial showed lower risks of recurrence-related events and death, while severe adverse events were more frequent with the combination.
- Regulatory applications based on the trial remain under review in the European Union, Japan and other markets.
AstraZeneca said on November 13, 2026, that the US Food and Drug Administration had approved Imfinzi with enfortumab vedotin before surgery, followed by Imfinzi alone after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The company described the decision in its November 13 press release.
VOLGA results support approval
The approval is based on the Phase III VOLGA trial, which enrolled 695 patients across 182 centres in 25 countries. Patients received three cycles of Imfinzi and enfortumab vedotin before surgery, followed by nine cycles of Imfinzi monotherapy.
In a planned interim analysis, the regimen reduced the risk of disease progression, recurrence, not undergoing surgery or death by 49% compared with radical cystectomy with or without approved adjuvant treatment. The overall survival analysis showed a 42% reduction in the risk of death.
Commercial outlook remains regional
At two years, 64% of patients receiving the combination remained alive and event-free, compared with 45% in the comparator arm. Overall survival was 78% versus 69%. Grade 3 and 4 adverse events occurred in 64% of patients in the combination group and 44% in the comparator group, while AstraZeneca reported no new safety signals.
AstraZeneca said the US decision represents a third bladder cancer indication for Imfinzi in two years. Applications based on the VOLGA results remain under review in the European Union, Japan and several other countries, leaving future international uptake as a key commercial issue.
AstraZeneca stock traded at 163.05 euros on Lang & Schwarz at 17:11 CET on Wednesday, November 18, 2026.
The Current market reports provide broader market context for the London-listed company.
More news and analyses on AstraZeneca stock.
AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Primary listing: London Stock Exchange
- Quoted price: 163.05 euros on Lang & Schwarz, Wednesday, November 18, 2026, at 17:11 CET
